13 Feb Colonoscopy Clinics in Singapore and Preventive Colon Health
Posted at 12:41h
in Colon Cancer
Illustration of colon polyps and early detection
Prof. Yeoh Khay Guan & Prof Patrick Tan[/caption]
Professor Patrick Tan, MD PhD
Dean, Duke-NUS Medical School;
Cancer and Stem Cell Biology Signature Research Programme,
Duke-NUS Medical School; and
Professor Yeoh Khay Guan, MBBS
Chief Executive, National University Health System;
Senior Consultant
Division of Gastroenterology and Hepatology
National University Hospital.
MedicalResearch.com: What is the background for this study?
Response: Gastric intestinal metaplasia (IM) is a precancerous condition that can arise in the stomach after long-term infection with Helicobacter pylori (a common stomach bacterium).
Clinically, IM is recognised as a risk state for gastric cancer (GC), as individuals with IM have 6-fold higher risk of eventually developing GC. However, not all IM patients will develop GC, and we lack an understanding of the biological processes operating within IM to transition to GC. Also, we don’t know if these processes are commonly found across the world, particularly since different countries have different rates of GC incidence.
In this study, we looked at DNA mutations and mutational signatures in IM samples collected from six countries with varying GC incidence (including accompanying blood-derived genetic variants). We wanted to understand potential risk factors for GC and how this information can be harnessed to improve the clinical management of IM patients and to reduce their GC risk.
Dr. Lång[/caption]
Kristina Lång MD PhD
Associate professor, Diagnostic Radiology
Translational Medicine, Lund University
Senior consultant, Unilabs Mammography Unit
Skåne University Hospital, Malmö, Sweden
MedicalResearch.com: What is the background for this study?
Response: Prior to the start of the trial, several retrospective studies had shown that AI could discriminate between screening mammograms at low and high risk of cancer, with performance comparable to that of average breast radiologists. These findings suggested a potential to improve both the efficiency and sensitivity of mammography screening. This motivated us to design and evaluate an AI-supported screening procedure in a randomised controlled trial. The MASAI trial was among the first prospective studies in this field and, to date, remains the only randomised trial with reported results on the use of AI in breast cancer screening.
In European breast cancer screening programmes, every mammogram is usually read by two radiologists, so called double reading, to ensure a high sensitivity. In the MASAI trial we compared AI-supported mammography screening to standard double reading without AI. I
n the AI-supported approach, mammograms identified as low-risk by the AI were read by a single radiologist, while high-risk mammograms underwent double reading, with AI providing additional detection support.
Image Source: Pexels[/caption]
Cancer research is rapidly evolving, and one of the most transformative areas of discovery is metabolic science. Traditionally, cancer has been viewed mainly through a genetic lens, with treatment strategies focused on destroying tumors or targeting DNA mutations. While these approaches remain essential, modern research shows that cancer is also deeply connected to how cells produce and use energy. By understanding metabolic behavior, clinicians are unlocking new opportunities to improve treatment precision, reduce side effects, and ultimately enhance patient outcomes.
The titanium heart implant is available as a clinical trial, and the operation was performed last year at the Duke University Medical Center. The new artificial heart, designed by BiVACOR, can pump 12 liters of blood to the body per minute through a magnetically suspended rotor. During the day the...
Dr. Davila[/caption]
MedicalResearch.com Interview with:
Marco Davila, MD, PhD
Hematologist/Oncologist,
Senior Vice President and Associate Director for Translational Research at
Roswell Park Comprehensive Cancer Center (Buffalo, NY) - study senior author
[caption id="attachment_71820" align="alignleft" width="150"]
Dr. Stone[/caption]
Co-author Meredith Stone, PhD
Assistant Director for Cell Therapy Translation
in Dr. Davila’s lab at Roswell Park - presenting author
MedicalResearch.com: What is the background for this study?
Response: While CD19-targeted CAR T cell therapy has garnered clinical success and FDA approval for the treatment of large B cell lymphoma, approximately half of patients suffer from primary resistance or relapse. Increasing evidence suggests that resistance mechanisms are supported by the tumor microenvironment (TME). Cytokines secreted by CAR T cells can remodel the TME, determining the phenotype and function of other immune cells.
Dr. Zak[/caption]
MedicalResearch.com Interview with:
Magdalena M. Żak, PhD
Zangi Lab
Instructor | Cardiovascular Research Institute
Instructor | Genetics & Genomic Sciences
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
New York, NY 10029
MedicalResearch.com: What is the background for this study?
Response: mRNA has proven to be a groundbreaking technology through COVID-19 vaccines, and most mRNA-based therapeutics in development today are still focused on vaccines. However, in principle, mRNA could be used for many diseases in which expression of a therapeutic protein would be beneficial. A major reason mRNA is less commonly used outside of vaccines is the lack of robust targeting: for vaccination, broad expression can be acceptable because the goal is antigen production for immune recognition, but for other applications - especially cancer - targeted delivery and minimized off-target expression are critical to reduce side effects. Current targeting strategies largely rely on lipid nanoparticles (LNPs), which act as lipid “carriers” for systemic delivery. Although LNPs can be designed to show some tissue tropism, this is often limited to organs such as the liver, spleen, and lungs.
Dr. Matthew Hirschey[/caption]
Matthew Hirschey Ph.D.
Associate Professor of Medicine
Associate Professor of Cell Biology
Associate Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Member of Sarah W. Stedman Nutrition and Metabolism Center
Hirschey Lab in the Duke Molecular Physiology Institute,
Duke University
MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed?
Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies.
We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.
Dr. Bian Jiang[/caption]
Jiang Bian, PhD
Associate Dean of Data Science
Walther and Regenstrief Professor of Cancer Informatics
Professor of Biostatistics & Health Data Science
Adjunct Professor, Biomedical Engineering and Informatics
Chief Data Scientist, Regenstrief Institute
Chief Data ScientistCustomize & Schedule Social Media Posts
Indiana University Health
[caption id="attachment_71230" align="alignleft" width="125"]
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Jiyoung Ahn[/caption]
MedicalResearch.com Interview with:
Jiyoung Ahn, PhD
Professor of Population Health, NYU Grossman School of Medicine
Associate Director for Population Science, NYU Perlmutter Cancer Center
NYU Langone Health
New York, NY 10016
MedicalResearch.com: What is the background for this study?
Response: About 10 years ago. we reported that people with poor oral health seem to have a greater risk of pancreatic cancer development. We suspected that this could be due to oral microbiota. More recently, animal studies, by other groups, showed that bacteria from the mouth can actually travel through saliva into the pancreas. But we didn’t know which exact species of bacteria or fungi might be involved in pancreas cancer development. We therefore conducted this large human study to examine the oral microbiome — including whole bacteria and fungi profiles in the mouth, and to see which bacteria and fungal taxa are associated with subsequent risk of pancreatic cancer development.
Dr. Wheless[/caption]
Lee Wheless, MD, PhD
Assistant Professor
Department of Dermatology
Department of Medicine, Division of Epidemiology
Vanderbilt University Medical Center
Staff Physician
Tennessee Valley Health System VA Medical Center
MedicalResearch.com: What is the background for this study?
Response: Nicotinamide has been in use for skin cancer prevention for at least a decade. A more recent trial among solid organ transplant recipients (SOTR) specifically concluded that there was no benefit in this population. While that study had a number of issues, it really led dermatologists to question whether it was efficacious. This coupled with another study around the same time that suggested that metabolites of nicotinamide might increase the risk of major adverse cardiovascular events (MACE).
My group earlier this year conducted a similar study to this one showing that we really did not observe any increase in MACE at the population level. We then turned to address of the question of if nicotinamide was actually useful in reducing skin cancer risk.
Freepix image[/caption]
Cancer is one of the most complex and heterogeneous diseases known to medicine. Tumors can differ not only between patients but also within a single individual, with subclones evolving over time and influencing how the disease progresses or responds to treatment. Next-generation sequencing (NGS) has become a critical tool in oncology, helping researchers and clinicians unravel this complexity at the molecular level.
By analyzing DNA and RNA at high resolution, NGS enables the detection of mutations, copy number changes, gene fusions, and expression patterns that shape tumor biology. This information provides insight into cancer drivers, mechanisms of resistance, and therapeutic targets. Importantly, it also supports precision medical oncology, where treatments are guided by the specific molecular features of a patient’s tumor rather than by one-size-fits-all approaches.
Dr. Minji Jung[/caption]
Minji Jung PharmD, PhD
Postdoctoral Research Fellow in Epidemiology
Department of Urology
Stanford University Medical Center
Stanford, CA
MedicalResearch.com: What is the background for this study?
Response: Hypertension is a well-established risk factor for kidney cancer, and previous studies have suggested potential links between antihypertensive medications and kidney cancer risk. However, distinguishing the effects of the medications from those of hypertension itself has been challenging. Our meta-analysis systematically evaluated different classes of antihypertensive drugs while accounting for hypertension.
Pexels image[/caption]
Cancer care is going through big changes due to advancement in healthcare research. For many years, the main treatments were surgery, chemotherapy, and radiation. These are still important, but now new options like immunotherapy and targeted therapy are improving results for patients. But with these new treatments also come new challenges.
They have completely changed how cancer clinics handle billing and payments. For oncology providers, keeping up with these changes is important to stay financially secure. This article looks at new cancer treatments, how they affect billing, the challenges clinics face, and how trusted oncology billing services providers help providers handle these issues.
Dr. Patel[/caption]
Rima Patel, MD
Assistant Professor
The Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Targeted treatment options for metastatic triple negative breast cancer (TNBC) are limited. TNBCs are associated with a high frequency of PTEN loss, which can lead to activation of the mTOR pathway and tumor proliferation but may be reversible with the mTOR inhibitor everolimus. A prior phase II single arm trial of carboplatin and everolimus in patients with advanced TNBC demonstrated good tolerability and preliminary efficacy. The current study is a randomized phase II trial comparing carboplatin and everolimus with carboplatin alone in patients with metastatic TNBC.
We found that the combination of carboplatin and everolimus reduced the risk of progression or death by 52%. The regimen was well tolerated and provides a promising treatment option for patients with advanced TNBC.
Dr. Campanella[/caption]
Gabriele Campanella, PhD
Assistant Professor
Windreich Department of Artificial Intelligence and Human Health
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study?
Response: Lung cancer is the most lethal cancer in the US. Lung adenocarcinoma (LUAD) is the most common form of lung cancer with an incidence of over 100k per year in the US. EGFR mutations are common driver mutations in LUAD, and importantly, these mutations can be targeted by TKI therapy, which has high response rates. Because of this, EGFR testing via NGS (Next Generation Sequencing) is considered mandatory by guidelines for any LUAD diagnosis.
In high-resource settings, rapid EGFR testing is done while waiting for confirmation via NGS. This is because NGS takes about 2 weeks on average, while the rapid testing has a median TAT of 2 days. Early treatment decisions could be made based on the rapid test results. Rapid tests have some important drawbacks, most notably, it exhausts tissue. In lung cancer, tissue is scarce in the first place, and up to 25% of cases, after rapid testing there is not enough tissue for NGS. In those circumstances, patients have to be biopsied again, which adds unnecessary risk for the patient. Even worse, in some cases, the NGS is never done. A non-tissue-exhaustive computational biomarker could be used instead of the tissue-based rapid test.
Dr. Hideyuki Saya, MD, PhD[/caption]
Hideyuki Saya, MD, PhD
Director, Oncology Innovation Center
Fujita Health University
Toyoake, Japan
MedicalResearch.com: What is the background for this study?
Response: Benzaldehyde, a simple aromatic compound found in the natural aroma of almonds and apricots, has long been reported to have anticancer activity, with clinical trials even conducted in Japan in the 1980s. However, the molecular mechanism underlying its anticancer effect has remained unclear for decades.
Our study was initiated by Dr. Jun Saito, whose father was one of the original researchers studying benzaldehyde. Driven by a personal motivation to clarify the scientific basis of this compound’s effect, Dr. Saito spent over a decade in our lab to finally uncover its mechanism of action.
Dr. Kirchhoff[/caption]
Tomas Kirchhoff, PhD (corresponding author)
Associate ProfessorLaura and Isaac Perlmutter Cancer Center
New York University School of Medicine
Robert Ferguson PhD
Senior Scientist at NYU Langone Medical Center
Kelsey Monson, PhD
Immuno-Oncology Postdoctoral Researcher
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study? Would you briefly explain how mitochondrial DNA differs from chromosomal DNA?
TK: Immune checkpoint blockade has changed the way we treat several cancers, including advanced melanoma. Before these therapies, the treatment options were very limited, but now more than half of patients experience significant tumor shrinkage or disease control.
KRM: Despite these advances, many patients still do not respond to treatment. One of the main challenges in cancer medicine today is to find ways to predict which patients will benefit from these therapies before treatment begins. This approach is key to personalizing care and improving outcomes.
RF: Mitochondria are small structures inside our cells that produce the energy needed for cells to function. Unlike most of our DNA, mitochondrial DNA is inherited only from the mother. Scientists can categorize this mitochondrial DNA into groups called haplogroups, based on unique variations in the genetic code. These haplogroups can provide insight into how cells produce energy and may affect a person’s health or response to cancer treatment.
Dr. Advani[/caption]
Pragati Advani MD, MPH, DrPH
Assistant Professor of Oncology, Department of Thoracic Surgery
And on faculty with the Department of Cancer Prevention and Population Sciences
Roswell Park Comprehensive Cancer Center
Buffalo, NY
MedicalResearch.com: What is the background for this study?
Response: In oncology, a study of second primary malignancy (SPM) is an emerging field that is predominantly driven by our success in identifying and treating the first primary cancers (FPCs). HPV is responsible for nearly a third of all infectious agent-related FPCs (including cancer of the oropharynx, anus, vulva, vagina, cervix and penis).
Advances in diagnostic and treatment methods have resulted in improved survivorship among these patients. However, they remain at risk for developing a SPM. No studies thus far had examined the risk of SPMs after HPV-associated FPCs, stratified by cancer site and gender.
Photo by Sonny Sixteen[/caption]
How hard is it to file a lawsuit for mesothelioma?
Besides the long latency period of the disease that makes it tough to connect the exposure to asbestos to your diagnosis, the legal side of things can be quite intimidating, to say the least. There are so many to consider, with multiple defendants that have their own interests to protect. Add to that a possible bankruptcy trust that can further complicate the compensation process.
As noted on the website https://www.usmesotheliomalaw.com/, when dealing with mesothelioma cases, you must first identify which product contains asbestos and what company is responsible for causing your illness. This can be quite difficult to do because some companies may no longer exist but have left behind trust funds for victims. The website provides an in-depth guide on how to tackle these complex legal matters and emphasizes the need to work with experienced mesothelioma lawyers to ensure all possible compensation avenues are explored.
So, what is the best way to tackle such a complicated situation?
Dr. Topalian[/caption]
Alique Topalian, PhD, MPH
Research Scientist
Family & Community Medicine | College of Medicine
University of Cincinatti
MedicalResearch.com: What is the background for this study?
Response: Adolescent and young adult (AYA) cancer survivors are diagnosed between the ages of 18-39. We have seen increases in cancer diagnoses in this younger population of about 1-2% per year with an estimated total increase of 30% between 2019-2030. Adolescent and young adult (AYA) cancer survivors experience early development of chronic medical conditions compared to healthy peers. Due to their young age at diagnosis and living decades beyond treatment, they are also at higher risk for second primary malignancies (SPM) and late effects than older adult-onset cancer survivors. Primary care providers are responsible for most long-term care of survivors and many are unfamiliar with the effects of cancer treatment in younger populations.
Dr. Jani[/caption]
Chinmay Jani, MD
Chief Fellow, Hematology & Oncology
University of Miami / Jackson Health System
[caption id="attachment_68874" align="alignleft" width="125"]
Dr. Lopes[/caption]
Gilberto Lopes, M.D.
Professor, Chief, Division of Medical Oncology
Associate Director for the Cancer Center and
Medical Director for International Affairs
Sylvester Comprehensive Cancer Center
MedicalResearch.com: What is the background for this study?
Response: There is growing evidence linking alcohol consumption to increased cancer risk and mortality. This association was recently emphasized by the former U.S. Surgeon General, prompting renewed public health interest. In response to these concerns, under the mentorship of Dr. Lopes, we evaluated national trends in alcohol-associated cancer mortality using data from the Global Burden of Disease database.
Dr Tong Li[/caption]
Dr Tong Li PhD | Cancer Institute NSW Early Career Fellow
Breast Cancer Clinical and Population Health Stream
The Daffodil Centre, Faculty of Medicine and Health, The University of Sydney
Moore Theological College | The University of Sydney | NSW | 2042
MedicalResearch.com: What is the background for this study?
Response: Having a family history of breast cancer is one of the most common risk factors for women. About 8% to 11% of women in the U.S. report having a close relative diagnosed with breast cancer. These women often have dense breasts. Dense breast tissue can make standard digital mammography (DM, also known as 2D mammography) less effective in detecting cancer. Digital breast tomosynthesis (DBT), a 3D imaging technology, has become increasingly used in breast cancer screening because it improves the visibility of lesions and reduces unnecessary callbacks. However, until now, it has been unclear whether DBT offers the same benefits in women with a family history of breast cancer, especially across different family risk levels and breast density types.
Dr. Andrei Bakin[/caption]
Andrei Bakin, PhD, Associate Professor of Oncology, Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center – first author of “A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response” and senior author of “Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities”
Christos Fountzilas, MD, FACP, Associate Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center - and senior author of “A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response”
Mohammed Alruwaili, MS, PhD, newly graduated doctoral candidate in Cancer Genetics & Genomics at Roswell Park Comprehensive Cancer Center, first author of “Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities”
Dr. Gokul Das[/caption]
First author Gokul Das, PhD, Professor of Oncology and Co-Director of the Breast Translational Group, Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center
Chetan Oturkar, PhD, Research Assistant Professor in the Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, first author on the study
MedicalResearch.com: What is the background for this study?
Dr. Gokul Das: Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer for which effective targeted therapies are not available, and which rapidly becomes resistant to chemotherapy. TNBC tumors are negative for estrogen receptor α (ERα), progesterone receptor (PR), and HER-2/neu receptor. Endocrine therapy or HER2-targeted therapies are not effective against TNBC. Currently available options including immunotherapy benefit only some patients. They are cost-prohibitive and have severe adverse effects. Therefore, there is an unmet need for rationally designed therapies for TNBC. Although ERα is absent in TNBC, majority of these tumors express estrogen receptor beta (ERβ), a structurally related but functionally distinct isoform of the estrogen receptor coded by a different gene. Tumor suppressor protein p53 is mutated in the majority (80%) of TNBC. p53, when mutated, loses its tumor suppression capabilities, and instead gains oncogenic or tumor-driving functions. One of the major oncogenic functions of mutant p53 is to bind and inactivate another tumor suppressor named p73. The Das laboratory has been focusing on the mechanisms underlying the estrogen receptor β-p53-p73 axis for discovering rational and effective therapeutic strategies against TNBC.
Dr. Siddiqui[/caption]
Mohamed Tausif Siddiqui, MD
The study’s lead author and a Gastroenterology fellow
Cleveland Clinic.
MedicalResearch.com: What is the background for this study?
Response: Our study looked at how the stage of gastric cancer diagnosis has changed over the past two decades in the U.S., using national SEER data. Gastric cancer has long been a challenge because it’s often diagnosed late, when treatment options are limited and survival rates are poor.
But with advancements in endoscopic technology—like high-definition imaging, narrow-band imaging, and endoscopic ultrasound—we wanted to see if these tools were making a difference in catching cancers earlier.
Dr. Robinson[/caption]
Ashley Robinson, MD, lead author
Second-year internal medicine resident
Advocate Lutheran General Hospital
MedicalResearch.com: What is the background for this study?
Response: Briefly, anal cancer makes up around 1% of gastrointestinal cancers and more than 90% of all anal cancers are caused by chronic human papillomavirus or HPV infections.
In previous research, it has been noted that women over the age of 65 have rates that were increasing more than other groups and myself along with my colleagues and the principal investigator of this project, Dr. Eli Ehrenpreis, wanted to further characterize these findings, looking into more specific details of these previously noted trends. Using data from a public database ran by the National Cancer Institute called the Surveillance, Epidemiology and End Results program, also known as SEER, and their statistical analysis software, SEER*Stat, we analyzed anal cancer incidence trends, looking at differences between sex, age, and ethnicity in order to further identify specific groups that have more rapidly increasing rates than others.
Dr. Corley[/caption]
Douglas Corley, MD, PhD
Chief Research Officer, The Permanente Medical Group
Kaiser Permanente, Northern California
MedicalResearch.com: What is the background for this study?
Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician.